Alpine Immune Sciences Inc (ALPN) Stock
ALPN is no longer traded. Alpine Immune Sciences was acquired by Vertex (VRTX) on May 20, 2024.
Each ALPN share was exchanged for $65.00 in cash. Prices on this page are historical; the last trade was May 17, 2024 at $64.97.
See Vertex (VRTX) stock →Alpine Immune Sciences stock price history
ALPN final trading statistics
- Final close
- $64.97
- Final trading day
- May 17, 2024
- Market cap at delisting
- $4.46B
- Shares outstanding
- 68.60M
- Final 52-week range
- $8.33 – $65.00
- Avg. volume (final 3 mo.)
- 2,358,490
- All-time high (split-adj.)
- $80.64 · Aug 2015
- All-time low (split-adj.)
- $2.15 · Mar 2020
- Return since IPO
- +8.9%
- Beta
- 0.97
- Book value / share
- $5.08
- Price / book
- 12.80
Alpine Immune Sciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $58.88M | -$32.2M | -$0.67 |
| FY2022 | $30.06M | -$57.8M | -$1.68 |
| FY2021 | $23.44M | -$50.3M | -$1.98 |
| FY2020 | $9.34M | -$27.9M | -$1.38 |
| FY2019 | $1.74M | -$42.5M | -$2.29 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.
Alpine Immune Sciences stock FAQ
What happened to Alpine Immune Sciences stock?
Alpine Immune Sciences was acquired by Vertex (VRTX) on May 20, 2024. Shareholders received $65.00 in cash for each share. ALPN stock stopped trading on the Nasdaq, with a final close of $64.97 on May 17, 2024.
What did Alpine Immune Sciences shareholders receive?
Each ALPN share was converted into $65.00 in cash. The deal was valued at about $4.9 billion.
Is ALPN stock still trading?
No. ALPN was delisted from the Nasdaq on May 20, 2024 and no longer trades on a U.S. exchange.
What was the last price of ALPN stock?
ALPN closed at $64.97 on its final trading day, May 17, 2024, for a market value of about $4.46B.
What were Alpine Immune Sciences's revenue and earnings in its last full fiscal year?
Alpine Immune Sciences reported revenue of $58.88M and net income of -$32.2M in fiscal 2023, its last full year as a public company.
When did Alpine Immune Sciences go public?
Alpine Immune Sciences Inc stock began trading on June 17, 2015.